KIDSNasdaqSurgical & Medical Instruments & ApparatusUS GAAP · USD

OrthoPediatrics Corp

OrthoPediatrics Corp. is a U.S.-based medical device company focused on orthopedic products designed specifically for children. Its portfolio includes implants, surgical instruments, specialized braces, and orthotic and prosthetic clinic services used by pediatric orthopedic surgeons, orthotists, and related care providers in the United States and international markets.

Kysy yhtiöstä
Liikevaihto236milj. USD
+15,4 %v/v
Liikevoitto (EBIT)−39,2milj. USD
−12,1 %v/v
EBIT-marginaali−16,6%
+0,5 %-yks.v/v
Nettotulos−39,6milj. USD
−4,8 %v/v
Vapaa kassavirta−16,0milj. USD
+61,4 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2020–2025

−1000100200300milj. USD2020: 71 milj. USD2020: EBIT −27 milj. USD20202021: 98 milj. USD2021: EBIT −18 milj. USD20212022: 122 milj. USD2022: EBIT −25 milj. USD20222023: 149 milj. USD2023: EBIT −27 milj. USD20232024: 205 milj. USD2024: EBIT −35 milj. USD20242025: 236 milj. USD2025: EBIT −39 milj. USD2025236−39
LiikevaihtoLiikevoitto (EBIT)
Kysy Clarifolta: OrthoPediatrics Corp

Liiketoiminta

Osuus liikevaihdosta
Surgical implants and instruments55 %

Anatomically appropriate implant systems and the instrument sets used in pediatric orthopedic procedures.

Specialized bracing25 %

Custom and off-the-shelf pediatric braces, including scoliosis and growth-modulation products.

Orthotic and prosthetic clinic services15 %

Clinic-based fitting and treatment services for children needing non-surgical orthopedic care.

Other pediatric orthopedic products5 %

Adjunct systems such as sports medicine, spine, and specialty procedure-specific products.

Tuotteet

Raportoitu · osuus liikevaihdosta
70,4%27,9%FY2025100 %
  • Traumaand Deformity70,4 %
  • Spine27,9 %
  • Sports Medicine and Other1,7 %

Lähde: 10-K FY2025, yhtiön tuotelinjoittain raportoima liikevaihto (SEC XBRL). Osuudet on laskettu näytetyistä riveistä ja ne summautuvat 100 %:iin.

Asiakkaat

The company sells primarily to pediatric orthopedic surgeons and the hospitals or medical facilities where they perform procedures. It also serves orthotists, physical therapists, and, in some cases, end customers directly through bracing and clinic-based care. Internationally, products are sold through distributors and sales agencies, while in selected markets the company uses direct sales to hospitals.

Pediatric orthopedic surgeons

Buy implant systems, instruments, and procedure-specific tools for trauma, deformity, scoliosis, and sports medicine cases.

Hospitals and medical facilities

Host consigned implant and instrument sets and purchase products when used or shipped, depending on market structure.

Orthotists and physical therapists

Buy or fit bracing products and support non-surgical pediatric orthopedic treatment.

Patients and families

Receive custom braces and clinic services, especially through the company's O&P clinics.

International distributors and agencies

Purchase or facilitate sales of implants and braces in overseas markets and manage local hospital relationships.

Strategia

The company is expanding its installed base of consigned implant and instrument sets to improve hospital coverage and increase procedure access. It is also broadening its pediatric orthopedic portfolio through research and development, product line extensions, and selective acquisitions, while extending its clinic network and international sales infrastructure.

Expand consigned inventory coverageLyhyt aikaväli

Pediatric orthopedic procedures often require full implant sets on site before revenue can be realized.

Broaden product portfolioKeskipitkä aikaväli

A wider offering improves surgeon adoption and addresses more pediatric orthopedic conditions.

Strengthen international distributionKeskipitkä aikaväli

Local sales and warehouse presence improves service levels and market access outside the U.S.

Expand O&P clinic networkKeskipitkä aikaväli

Clinic services deepen the company’s role in non-surgical pediatric orthopedic care.

Maantiede

Q1/2026

OrthoPediatrics is headquartered in Warsaw, Indiana and sells in the United States and more than 75 countries internationally. The company has direct sales programs in selected markets such as the UK, Ireland, Australia, New Zealand, Canada, Belgium, the Netherlands, Italy, Germany, Switzerland, and Austria, and it operates warehouses and local entities in Europe and Australia to support distribution. Its manufacturing footprint includes in-house bracing production in Iowa, the UK, and Boston, while most implants and instruments are produced in the United States through contract manufacturing.

USA76 %
Other countries (US filing)24 %

Osuus liikevaihdosta, jonka yhtiö raportoi maantieteellisesti.

Riskit

The business depends on elective pediatric procedures, surgeon adoption, and hospital access, so disruptions in procedure volumes or reimbursement can affect demand. International operations add exposure to distributor credit risk, product returns, trade compliance, and foreign market execution, while the company’s inventory-heavy model requires careful management of consigned sets and working capital.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Surgeon adoption and training risk1Regulatory and reimbursement risk2Inventory and consignment risk4International credit and return risk5
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Surgeon adoption and training riskVaikutus: KorkeaTodennäköisyys: Kohtalainen

    Products require surgeon familiarity and proper technique; weak adoption can limit sales growth.

    Kohdistuu: All implant and instrument systems

  2. Regulatory and reimbursement riskVaikutus: KorkeaTodennäköisyys: Kohtalainen

    Medicaid and other payer changes can affect reimbursement for pediatric orthopedic procedures.

    Kohdistuu: U.S. clinic and procedure reimbursement

  3. Elective surgery volume disruptionVaikutus: Korkea

    Most products are used in elective pediatric procedures, so hospital postponements reduce utilization.

    KohdistuuTraumaDeformityScoliosis procedures
  4. Inventory and consignment riskVaikutus: KeskitasoTodennäköisyys: Kohtalainen

    The model requires substantial upfront investment in hospital consignment sets and inventory.

    Kohdistuu: Implants and instruments held on consignment

  5. International credit and return riskVaikutus: KeskitasoTodennäköisyys: Matala

    Overseas customers may return products and some distributors are thinly capitalized.

    Kohdistuu: Distributor-led international sales

Kysy Clarifolta: OrthoPediatrics Corp

Kirjanpito

Harkinnanvaraiset erät
Revenue recognition by channel

Different recognition points for implants, braces, and clinics affect quarter-to-quarter comparability.

Vaikutus: Implants on consignment, shipped braces, and fitted clinic services

Estimated contractual allowances and concessions

Clinic revenue is recorded net of expected reimbursement and later claim adjudication adjustments.

Vaikutus: Reported revenue and accounts receivable

Consigned inventory accounting

Inventory remains on the balance sheet until used in surgery, affecting working capital and cost timing.

Vaikutus: Inventory, cost of revenue, and gross margin

Seasonality

Procedure volumes are higher in summer and holiday periods, affecting quarterly revenue patterns.

Vaikutus: Revenue comparability across quarters

Samankaltaisia listattuja yhtiöitä

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

Dynatronics Corp

DYNTQ · Surgical & Medical Instruments & Apparatus

Orthofix Medical Inc.

OFIX · Surgical & Medical Instruments & Apparatus

Globus Medical, Inc

GMED · Surgical & Medical Instruments & Apparatus

U.S. Physical Therapy, Inc

USPH · Services-Health Services

Stryker Corporation

SYK · Surgical & Medical Instruments & Apparatus

IR-Med, Inc.

Electromedical & Electrotherapeutic Apparatus

Päivitetty: 24.9.2026

OrthoPediatrics Corp (KIDS) liikevaihto, tulos ja tunnusluvut 2025 – Clarifo